Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT07723261 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT07723261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Recruiting
Start date
March 30, 2026
Completion date
March 30, 2029
Enrollment
70 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma (pdac)